SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	During the first quarter of 2017, we sold a total of 3,104,253 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $31.6 million at an average selling price of $10.18 per share. Net proceeds were approximately $31 million after deducting commissions and other transactions costs. On March 9, 2017, we announced the pricing of an underwritten public offering of 5,128,206 shares of our common stock (plus a 30-day underwriter option to purchase up to an additional 769,230 shares of common stock, which has been exercised) at a price of $9.75 per share, with expected gross proceeds to TG Therapeutics of $57.5 million, less underwriting discounts and commissions. Total net proceeds from this offering, including the overallotment, are $54 million, net of underwriting discounts and estimated offering expenses of approximately $3.5 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-201339) that was previously filed and declared effective by the SEC in January 2015. The offering closed on March 14, 2017.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2016

During the first quarter of 2017, we sold a total of 3,104,253 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $31.6 million at an average selling price of $10.18 per share. Net proceeds were approximately $31 million after deducting commissions and other transactions costs.

On March 9, 2017, we announced the pricing of an underwritten public offering of 5,128,206 shares of our common stock (plus a 30-day underwriter option to purchase up to an additional 769,230 shares of common stock, which has been exercised) at a price of $9.75 per share, with expected gross proceeds to TG Therapeutics of $57.5 million, less underwriting discounts and commissions. Total net proceeds from this offering, including the overallotment, are $54 million, net of underwriting discounts and estimated offering expenses of approximately $3.5 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-201339) that was previously filed and declared effective by the SEC in January 2015. The offering closed on March 14, 2017.